Denver, Colorado, October 1, 2012 – Burg Simpson Eldredge Hersh & Jardine, P.C. is pleased to announce that shareholder Seth A. Katz has been appointed by the Hon. David R. Herndon, United States District Court Chief Judge for the Southern District of Illinois, to serve as Co-Lead counsel in the Multidistrict Litigation In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL No. 2385.
Mr. Katz has been appointed Co-Lead Counsel, meaning he is one of the lawyers to have been selected to lead the litigation nationally against the maker of Pradaxa, Boehringer Ingelheim. To date, hundreds of patients have filed lawsuits claiming that the blood thinning drug caused them uncontrollable bleeding, other serious injuries, and in some cases death.
Speaking of his appointment Mr. Katz said, “It is truly an honor and a privilege to be selected by Judge Herndon as one of the lawyers to lead this litigation. It is quite humbling to know that such a distinguished judge has the confidence in me to appoint me to such an important role in such an important litigation. I plan to fully devote myself to making sure that people injured by Pradaxa receive fair compensation for their injuries.”
First approved in October 2010, Pradaxa (Dabigatran Etexilate) is an anticoagulant known as a direct thrombin inhibitor. Prescribed to help reduce the risk of stroke and blood clots in patients with non-valvular atrial fibrillation (AFib), Pradaxa is marketed as an alternative to Warfrin (commonly known as Coumadin) — previously the standard, front-line therapy for AFib for more than 50 years. Unlike Warfarin, however, which can be reversed in the event of an emergency or bleeding event, Pradaxa has no known reversal agent. According the FDA, more than 1.1 million Pradaxa prescriptions have been dispensed since 2010.
Seth A. Katz is one of America’s leading trial attorneys. In January 2011, Mr. Katz was appointed to the Plaintiffs’ Steering Committee in the In re DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation (MDL 2197) by the Hon. David A. Katz, pending in the Northern District of Ohio. Mr. Katz is also currently the chair of the Discovery Committee in the YAZ/Yasmin (Drospirenone) Marketing, Sales Practices, and Products Liability Litigation (MDL 2100) pending in the Southern District of Illinois, and the In Re: Gadolinium-Based Contrast Agents Products Liability Litigation (MDL 1909), pending in the Northern District of Ohio. Mr. Katz is the inaugural President of the Mass Tort Trial Lawyers Association and for more than ten years has focused his practice on pharmaceutical and medical device litigation.
Burg Simpson is national leader in product liability and pharmaceutical litigation, having successfully litigated thousands of cases in state and federal courts over the last 30 years. The firm has obtained more the $1 billion in successful verdicts, settlements and judgments on behalf of its clients, and secured more than 100 individual recoveries in excess of $1 million.
The firm’s attorneys have held prominent leadership roles in litigation involving the Yasmin/Yaz birth control pill, the Ortho Evra birth control patch, the blood thinner Heparin, Gadolinium-Based contrast agents used in MRI scans, the pain medication Bextra/Celebrex, the anti-inflammatory drug Vioxx, and the drug Zyprexa, used to treat schizophrenia and bipolar disorders.
With offices in Denver, Cincinnati, Cody, and Phoenix, Burg Simpson Eldredge Hersh & Jardine, P.C., is a firm of award winning national trial lawyers, practicing in the areas of personal injury, mass torts, class actions, medical malpractice, dangerous drug litigation, defective products, insurance bad faith, employment law, workers compensation, social security disability, commercial litigation, and securities litigation.
# # #